Marker Therapeutics

MRKR · NASDAQ

$1.16−$0.04 (−3.33%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.20

Latest news

Press releaseOct 19, 7:00 AM ETGlobe Newswire
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
NewsOct 16, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseSep 22, 8:00 AM ETGlobe Newswire
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
NewsAug 25, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 18, 5:31 PM ETGlobe Newswire
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Press releaseFeb 18, 8:00 AM ETGlobe Newswire
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Press releaseJan 26, 7:00 AM ETGlobe Newswire
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology
Press releaseJan 5, 7:00 AM ETGlobe Newswire
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Press releaseNov 14, 7:00 AM ETGlobe Newswire
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Press releaseNov 5, 7:30 AM ETGlobe Newswire
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Press releaseNov 3, 9:15 AM ETGlobe Newswire
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Press releaseOct 6, 7:30 AM ETGlobe Newswire
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Press releaseAug 28, 8:00 AM ETGlobe Newswire
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
NewsAug 26, 12:34 PM ETVandana Singh
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Press releaseAug 26, 7:00 AM ETGlobe Newswire
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Press releaseJul 30, 8:00 AM ETGlobe Newswire
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
NewsJul 17, 10:12 AM ETAvi Kapoor
Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings
Press releaseJun 17, 8:00 AM ETGlobe Newswire
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Press releaseMay 20, 8:00 AM ETGlobe Newswire
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Press releaseMar 31, 8:45 AM ETGlobe Newswire
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
NewsMar 14, 8:10 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseFeb 25, 7:00 AM ETGlobe Newswire
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Press releaseDec 19, 8:06 AM ETGlobe Newswire
Marker Therapeutics Announces $16.1 Million Private Placement
Press releaseDec 19, 8:05 AM ETGlobe Newswire
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
Press releaseDec 17, 7:00 AM ETGlobe Newswire
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Press releaseDec 10, 8:30 AM ETGlobe Newswire
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
Press releaseNov 26, 11:00 AM ETGlobe Newswire
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
Press releaseNov 14, 4:30 PM ETGlobe Newswire
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Press releaseAug 14, 4:30 PM ETGlobe Newswire
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Press releaseAug 12, 7:00 AM ETGlobe Newswire
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

12 Health Care Stocks Moving In Friday's Intraday Session

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

12 Health Care Stocks Moving In Tuesday's After-Market Session

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

12 Health Care Stocks Moving In Friday's Pre-Market Session

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma